Dyne Therapeutics Reports Earnings, Surpasses Expectations

Dyne Therapeutics (NASDAQ:DYN) released its quarterly earnings results on Thursday. The company announced an earnings per share (EPS) of ($0.88) for the quarter, which exceeded analysts' consensus estimates of ($0.92) by $0.04, according to reports.

Dyne Therapeutics Stock Performance

On Thursday, Dyne Therapeutics shares fell by $0.62, bringing the stock to $13.17. A total of 2,055,570 shares were traded, slightly below the average trading volume of 2,280,310 shares. Over the past year, the stock has reached a low of $13.05 and a high of $47.45. The company's 50-day moving average stands at $17.19, while the 200-day moving average is $27.93. Dyne Therapeutics has a market capitalization of $1.34 billion, a price-to-earnings ratio of -3.70, and a beta of 1.11.

Insider Trading Activity

In recent insider trading news, Senior Vice President Richard William Scalzo sold 1,455 shares of Dyne's stock on December 11, receiving an average price of $28.12 per share, totaling approximately $40,914.60. After this transaction, Scalzo holds 127,078 shares valued at around $3,573,433.36, reflecting a 1.13% decrease in his ownership. Another insider, Oxana Beskrovnaya, also sold shares on the same day, offloading 2,334 shares at the same average price, totaling about $65,632.08. Beskrovnaya now retains 201,685 shares valued at approximately $5,671,382.20, marking a 1.14% reduction in her ownership. Over the last ninety days, insiders have sold a cumulative total of 6,387 shares worth about $142,789, and corporate insiders own 20.77% of the company's stock.

Analyst Recommendations

Wall Street analysts have recently shared their views on Dyne Therapeutics. HC Wainwright reiterated a "buy" rating, providing a price target of $55.00 in a report released on January 10. Chardan Capital also reaffirmed a "buy" rating, setting a price target of $50.00 for the shares. Guggenheim repeated its "buy" recommendation on January 24. Robert W. Baird initiated coverage with an "outperform" rating and price target of $46.00. Lastly, on December 12, Baird R.W. upgraded the stock to a "strong-buy" status. Current ratings show that one analyst rates the stock as a sell, one as a hold, ten as buys, and two as strong buys. According to MarketBeat, Dyne Therapeutics has an average rating of "Moderate Buy" and an average price target of $49.91.

Company Overview

Dyne Therapeutics, Inc. is a clinical-stage biotechnology company based in the United States that focuses on developing therapies for genetically driven muscle diseases. The company is working on a diverse portfolio of therapeutics aimed at conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and other rare muscle diseases. Dyne Therapeutics employs its FORCE platform to deliver disease-modifying treatments.

Earnings, Stocks, Performance